New at Pivot Park – CheckMark Labrecruitment
Since December 1st Checkmark Labrecruitment is present at Pivot Park.
Read more
ImmunoPrecise to Acquire ModiQuest Research BV
IMMUNOPRECISE ANTIBODIES LTD. announces that it has signed a binding letter of intent with ModiQuest Research BV.
Read more
Anglo-Dutch research teams awarded Eurostars funding for a €1.1M project to develop a synthetic matrix for 3D organoid cell culture
Researchers at Maastricht University, Noviocell BV (based at Pivot Park) and Cell Guidance Systems Ltd are collaborating on an EU funded Eurostars project to develop fully-defined matrices for the 3D culture of organoids.
Read more
US FDA APPROVES ASTRAZENECA’S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA
AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to CALQUENCE® (acalabrutinib).
Read more
Novel synergistic combinations identified by unbiased high-throughput screening
A high-throughput screening approach to identify novel synergistic drug combinations has been launched by NTRC.
Read more
Mirjam Mol neemt afscheid van Pivot Park
Mirjam Mol-Arts neemt afscheid als directeur van Pivot Park en het Pivot Park Screening Centre.
Read more
New at Pivot Park – ChardonPharma
Chardon Pharma recently moved into their laboratory in Pivot Park's Chesbrough Building.
Read more
New at Pivot Park – NanoServe
NanoServe has opened the doors of its office and laboratory at Pivot Park.
Read more
NTRC announces approval of key TTK kinase inhibitor patent
NTRC today announced that the USPTO has granted patent protection for a key patent for its TTK kinase inhibitor programme.
Read more